First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Item
http://www.wikidata.org/entity/Q31112375
Distinct Roles of Wnt/β-Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis in East Asian.The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis.Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.Nintedanib for the treatment of idiopathic pulmonary fibrosis.Nintedanib for Idiopathic Pulmonary Fibrosis.Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.Idiopathic pulmonary fibrosis: pathogenesis and management.Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosisUtility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective studyNintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
P2860

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Item
http://www.wikidata.org/entity/Q31112375
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@ast
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@en
type
label
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@ast
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@en
prefLabel
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@ast
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932
P356
P1433
P1476
First Data on Efficacy and Saf ...... y of ≤50 % of Predicted Value.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932